C07K16/1267

Methods of treating viral infections by administering an antibody preparation comprising IGG, IGA and IGM

An antibody preparation suitable for intravenous administration in humans includes IgG, IgA and at least 5% IgM antibodies by weight of the total amount of antibodies. The preparation is prepared from human plasma, has specific complement activating activity, and, in an in vitro assay with human serum suitable to determine the ability of the antibody preparation to activate complement unspecifically, the antibody preparation generates substantially no C5a and/or substantially no C3a. The antibody preparation can have medical uses.

Isolating a target analyte from a body fluid

The invention generally relates to using magnetic particles and magnets to isolate a target analyte from a body fluid sample. In certain embodiments, methods of the invention involve introducing magnetic particles including a target-specific binding moiety to a body fluid sample in order to create a mixture, incubating the mixture to allow the particles to bind to a target, applying a magnetic field to capture target/magnetic particle complexes on a surface, and washing with a wash solution that reduces particle aggregation, thereby isolating target/magnetic particle complexes.

Complete genome sequence of the methanogen <i>Methanobrevibacter ruminantium</i>

The present invention includes the complete genome sequence for the methanogen, Methanobrevibacter ruminan-tium, including polynucleotides which encode M. ruminantium polypeptides or peptides, as well as polynucleotides from non-coding regions. Also included are the encoded M. ruminantium polypeptides and peptides, and antibodies directed to these peptides or polypeptides, in addition to expression vectors and host cells for producing these peptides, polypeptides, polynucleotides, and antibodies. The invention further includes methods and compositions for detecting, targeting, and inhibiting microbial cells, especially methanogen cells such as M. ruminantium cells, using one or more of the disclosed peptides, polypeptides, polynucleotides, antibodies, expression vectors, and host cells.

Polypeptides derived from <i>Enterococcus </i>and their use for vaccination and the generation of therapeutic antibodies

Medicament for the treatment or the prevention of a bacterial infection, characterized in that it contains at least one polypeptide selected from the group of SEQ ID NO: 1 to SEQ ID NO: 9, and contiguous fragments thereof, wherein said at least one polypeptide or contiguous fragment thereof induces opsonic antibodies in a patient in need thereof. The polypeptides or the contiguous fragments thereof according to the present invention can be used for the preparation of a vaccine against an infection against Enterococcus.

ANTIBODY FOR HAIR IMPROVEMENT USE
20210317194 · 2021-10-14 ·

The present disclosure provides a composition and a method both for improving the hair. In one embodiment, the hair is improved using an antibody. In one embodiment, the antibody is produced using a bacterium occurring on the scalp or a hair root as an immunogen. In one aspect, the present invention also provides a method for improving the hair in a subject, including the step of administering an antibody produced using a microorganism-derived substance as an immunogen to the subject. The antibody according to the present invention may be administered in the form of a composition. According to the present invention, the promotion of hair growth or the prevention of hair loss can be achieved.

ANTIBODY SPECIFIC TO ALPHA-TOXIN OF STAPHYLOCOCCAL AUREUS AND USES THEREOF
20210317193 · 2021-10-14 ·

The present disclosure relates to an antibody or antigen-binding fragment thereof that specifically bind to α-toxin of Staphylococcal aureus. The present disclosure also relates to a pharmaceutical composition, a method for treating and/or preventing diseases and/or disorders caused by Staphylococcal aureus infection in a subject in need, and a method for detecting α-toxin of Staphylococcal aureus in a sample.

Human antibody specifically binding to acne bacteria using phage display technique, and use thereof

The present invention relates to a human antibody specifically binding to an acne-inducing bacterium using phage display technology and a use thereof, and more particularly, an antibody specifically binding to an antigen; a human antibody including the same; phage display technology using the same; and a cosmetic composition and a pharmaceutical composition using the same.

COMPLETE GENOME SEQUENCE OF THE METHANOGEN METHANOBREVIBACTER RUMINANTIUM

The present invention includes the complete genome sequence for the methanogen, Methanobrevibacter ruminan-tium, including polynucleotides which encode M. ruminantium polypeptides or peptides, as well as polynucleotides from non-coding regions. Also included are the encoded M. ruminantium polypeptides and peptides, and antibodies directed to these peptides or polypeptides, in addition to expression vectors and host cells for producing these peptides, polypeptides, polynucleotides, and antibodies. The invention further includes methods and compositions for detecting, targeting, and inhibiting microbial cells, especially methanogen cells such as M. ruminantium cells, using one or more of the disclosed peptides, polypeptides, polynucleotides, antibodies, expression vectors, and host cells.

Separating target analytes using alternating magnetic fields

The invention generally relates to using magnetic particles and alternating magnet fields to separate a target analyte from a sample. In certain embodiments, methods of the invention involve contacting a sample with magnetic particles including first moieties specific for a target analyte, thereby forming target/particle complexes in the sample, flowing the sample through a channel including second moieties attached to at least one surface of the channel, applying alternating magnetic fields to the flowing sample to result in target/particle complexes being brought into proximity of the surface to bind the second moieties and unbound particles remaining free in the sample, binding the target/particle complexes to the second moieties, and washing away unbound particles and unbound analytes of the sample.

Combined enteropathogen recombinant construct

The inventive subject matter relates to a construct comprising antigens derived from multiple enterobacteria including Campylobacter jejuni capsule polysaccharide polymer, enterotoxigenic Escherichia coli recombinant polypeptide construct and lipopolysaccharide from Shigella spp. The subject invention also relates to a method of inducing an immune response utilizing the inventive composition.